MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance

Parkin D.M. , Bray F. , Ferlay J. and Pisani P. , Estimating the world cancer burden: Globocan 2000, Int J Cancer 94 (2001), 153-6.

Dhanasekaran R. , Limaye A. and Cabrera R. , Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics, Hepat Med 4 (2012), 19-37.

Calvisi D.F. , Ladu S. , Gorden A. , Farina M. , Lee J.S. , Conner E.A. , Schroeder I. , Factor V.M. and Thorgeirsson S.S. , Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma, J Clin Invest 117 (2007), 2713-22.

Memeo R. , de Blasi V. , Cherkaoui Z. , Dehlawi A. , De' Angelis N. , Piardi T. , Sommacale D. , Marescaux J. , Mutter D. and Pessaux P. , New Approaches in Locoregional Therapies for Hepatocellular Carcinoma, J Gastrointest Cancer 47 (2016), 239-46.

Cho Y.K. , Kim J.K. , Kim M.Y. , Rhim H. and Han J.K. , Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology 49 (2009), 453-9.

Yeo W. , Mok T.S. , Zee B. , Leung T.W. , Lai P.B. , Lau W.Y. , Koh J. , Mo F.K. , Yu S.C. , Chan A.T. , Hui P. , Ma B. , Lam K.C. , Ho W.M. , Wong H.T. , Tang A. and Johnson P.J. , A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma, J Natl Cancer Inst 97 (2005), 1532-8.

Gish R.G. , Porta C. , Lazar L. , Ruff P. , Feld R. , Croitoru A. , Feun L. , Jeziorski K. , Leighton J. , Gallo J. and Kennealey G.T. , Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J Clin Oncol 25 (2007), 3069-75.

Li L. , Wei X.H. , Pan Y.P. , Li H.C. , Yang H. , He Q.H. , Pang Y. , Shan Y. , Xiong F.X. , Shao G.Z. and Zhou R.L. , LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling, Oncogene 29 (2010), 5785-95.

Wang X.Q. , Ongkeko W.M. , Chen L. , Yang Z.F. , Lu P. , Chen K.K. , Lopez J.P. , Poon R.T. and Fan S.T. , Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway, Hepatology 52 (2010), 528-39.

Tsang W.P. and Kwok T.T. , Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells, Oncogene 26 (2007), 4877-81.

Aller S.G. , Yu J. , Ward A. , Weng Y. , Chittaboina S. , Zhuo R. , Harrell P.M. , Trinh Y.T. , Zhang Q. , Urbatsch I.L. and Chang G. , Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding, Science 323 (2009), 1718-22.

Broxterman H.J. , Gotink K.J. and Verheul H.M. , Understanding the causes of multidrug resistance in cancer: A comparison of doxorubicin and sunitinib, Drug Resist Updat 12 (2009), 114-26.

Shukla G.C. , Singh J. and Barik S. , MicroRNAs: Processing, maturation, target recognition and regulatory functions, Mol Cell Pharmacol 3 (2011), 83-92.

Hung C.H. , Chiu Y.C. , Chen C.H. and Hu T.H. , MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression, and therapeutic target, Biomed Res Int 2014 (2014), 486407.

Xiong G. , Wang Y. , Ding Q. and Yang L. , Hsa-mir-1269 genetic variant contributes to hepatocellular carcinoma susceptibility through affecting SOX6, Am J Transl Res 7 (2015), 2091-8.

Liu L. , Qu W. and Zhong Z. , Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC, Int J Clin Exp Pathol 8 (2015), 5609-13.

Tang B. , Lei B. , Qi G. , Liang X. , Tang F. , Yuan S. , Wang Z. , Yu S. and He S. , MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression, J Exp Clin Cancer Res 35 (2016), 93.

Giannelli G. , Bergamini C. , Fransvea E. , Marinosci F. , Quaranta V. and Antonaci S. , Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion, Lab Invest 81 (2001), 613-27.

Fornari F. , Gramantieri L. , Giovannini C. , Veronese A. , Ferracin M. , Sabbioni S. , Calin G.A. , Grazi G.L. , Croce C.M. , Tavolari S. , Chieco P. , Negrini M. and Bolondi L. , MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells, Cancer Res 69 (2009), 5761-7.

Fornari F. , Milazzo M. , Chieco P. , Negrini M. , Calin G.A. , Grazi G.L. , Pollutri D. , Croce C.M. , Bolondi L. and Gramantieri L. , MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells, Cancer Res 70 (2010), 5184-93.

Sarkar F.H. , Li Y. , Wang Z. , Kong D. and Ali S. , Implication of microRNAs in drug resistance for designing novel cancer therapy, Drug Resist Updat 13 (2010), 57-66.

Wang Z. , Li Y. , Ahmad A. , Azmi A.S. , Kong D. , Banerjee S. and Sarkar F.H. , Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance, Drug Resist Updat 13 (2010), 109-18.

Meng F. , Henson R. , Lang M. , Wehbe H. , Maheshwari S. , Mendell J.T. , Jiang J. , Schmittgen T.D. and Patel T. , Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines, Gastroenterology 130 (2006), 2113-29.

Laurila E.M. and Kallioniemi A. , The diverse role of miR-31 in regulating cancer associated phenotypes, Genes Chromosomes Cancer 52 (2013), 1103-13.

Ruoming W. , Zhen Y. , Tengteng Z. and Jisheng H. , Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2, Cancer Gene Ther 22 (2015), 564-72.

Edmonds M.D. , Boyd K.L. , Moyo T. , Mitra R. , Duszynski R. , Arrate M.P. , Chen X. , Zhao Z. , Blackwell T.S. , Andl T. and Eischen C.M. , MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer, J Clin Invest 126 (2016), 349-64.

Xu T. , Qin L. , Zhu Z. , Wang X. , Liu Y. , Fan Y. , Zhong S. , Zhang X. , Xia L. , Xu C. and Shen Z. , MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin alpha5, Oncotarget 7 (2016), 27445-57.

Zhou R.J. , Xu X.Y. , Liu B.X. , Dai W.Z. , Cai M.Q. , Bai C.F. , Zhang X.F. , Wang L.M. , Lin L. , Jia S.Z. and Wang W.H. , Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells, Int J Mol Med 36 (2015), 1159-64.

Yang C. , Wang Y. , Hao C. , Yuan Z. , Liu X. , Yang F. , Jiang H. , Jiang X. , Zhou P. and Ding K. , IER5 promotes irradiation- and cisplatin-induced apoptosis in human hepatocellular carcinoma cells, Am J Transl Res 8 (2016), 1789-98.

Yamanaka N. , Okamoto E. , Toyosaka A. , Mitunobu M. , Fujihara S. , Kato T. , Fujimoto J. , Oriyama T. , Furukawa K. and Kawamura E. , Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis, Cancer 65 (1990), 1104-10.

Xu H. , Ma J. , Zheng J. , Wu J. , Qu C. , Sun F. and Xu S. , MiR-31 functions as a tumor suppressor in lung adenocarcinoma mainly by targeting HuR, Clin Lab 62 (2016), 711-8.

Rajbhandari R. , McFarland B.C. , Patel A. , Gerigk M. , Gray G.K. , Fehling S.C. , Bredel M. , Berbari N.F. , Kim H. , Marks M.P. , Meares G.P. , Sinha T. , Chuang J. , Benveniste E.N. and Nozell S.E. , Loss of tumor suppressive microRNA-31 enhances TRADD/NF-kappaB signaling in glioblastoma, Oncotarget 6 (2015), 17805-16.

Zhang X.B. , Song L. , Wen H.J. , Bai X.X. , Li Z.J. and Ma L.J. , Upregulation of microRNA-31 targeting integrin alpha5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells, Tumour Biol 37 (2016), 8317-25.

Xu Y. , Xia F. , Ma L. , Shan J. , Shen J. , Yang Z. , Liu J. , Cui Y. , Bian X. , Bie P. and Qian C. , MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest, Cancer Lett 310 (2011), 160-9.